foveciclib

Foveciclib (SY-5609) is a potent, selective, and orally bioavailable inhibitor of cyclin-dependent kinase 7 (CDK7). CDK7 is a critical regulator of both the cell cycle, where it acts as a CDK-activating kinase (CAK), and transcription, where it phosphorylates the RNA polymerase II C-terminal domain to facilitate gene expression. By targeting CDK7, foveciclib disrupts the transcription of key oncogenic drivers such as MYC and MCL1 and inhibits cell cycle progression, making it a promising therapeutic for various cancers. Originally developed by Syros Pharmaceuticals, the drug is being co-developed in Greater China by QiLu Pharmaceutical. It is currently being investigated in clinical trials for solid tumors, including pancreatic cancer, colorectal cancer, and hormone receptor-positive (HR+)/HER2-positive breast cancer, where it is often evaluated in combination with endocrine therapies or other targeted agents to overcome treatment resistance.

Other names

foveciclibSY-5609SY5609SY 5609